Objective: No standard treatment has been established for poorly differentiated neuroendocrine carcinoma; the usual recommended treatment is based on the strategy for small cell lung carcinoma. The aim of this study was to evaluate the response of poorly differentiated neuroendocrine carcinoma to the combination of irinotecan and cisplatin in one institution. Methods: We retrospectively reviewed 50 poorly differentiated neuroendocrine carcinoma patients treated from September 2005 to April 2011 in our institution. Patients were divided into two stages: limited disease or extensive disease. Forty-four patients received the combination chemotherapy of irinotecan and cisplatin, consisting of 4-week cycles of 60 mg/m 2 irinotecan on days 1, 8, 15 and 60 mg/m 2 cisplatin on day 1. Results and conclusion: Median age was 60 years. Median follow-up time was 11.4 months. Overall survival did not reach the median, and 1-year overall survival was 67%. The response rate was 50% (64% at first line), and progression-free survival was 4.8 months (7.3 months at first line). Grade 3 -4 hematologic adverse events were seen in 29 patients (66%) and Grade 3 -4 non-hematologic adverse events were seen in 20 patients (45%), but no patients died of adverse events. Multivariate analysis showed a statistically significant relationship with neuronspecific enolase elevation and poor overall survival (P ¼ 0.016, hazard ratio 6.261, 95% confidence interval). The combination chemotherapy of irinotecan and cisplatin is moderately effective and feasible, and it should be considered as a treatment option for poorly differentiated neuroendocrine carcinoma.
INTRODUCTION
Neuroendocrine carcinomas are components of neoplasms that have immunohistochemical staining characteristics (chromogranin A, synaptophysin and CD56/NCAM) or ultrastructural features (neurosecretory granules). Prognoses of neuroendocrine carcinoma patients are various, and for some of them, especially poorly differentiated neuroendocrine carcinoma (PDNEC) patients, it is poor. PDNEC arises from almost all organs and some components are similar to small cell lung carcinoma (SCLC) in morphology and are called extrapulmonary small cell carcinoma (EPSCC). EPSCC was first described in 1930 by Duguid and Kennedy (1) and accounts for 0.1 -0.4% of all malignancies, and 5% of all small cell carcinomas (2, 3) . In lung carcinoma, large cell carcinomas with neuroendocrine characteristics are called large cell neuroendocrine carcinoma (LCNEC) and LCNEC patients have recently been known to have as poor prognoses as SCLC patients (4) . Other than lung carcinoma, in clinical practice, PDNEC and EPSCC are usually treated in the same way. Because of their rarity, however, there has not been enough clinical data to establish a treatment strategy for PDNEC patients. The usual recommendation is to use the same treatment strategy as for SCLC.
For a long time, the standard systemic chemotherapy for advanced SCLC has been a combination of cisplatin (CDDP) and etoposide (EP regimen) (5, 6) . Recently, combined cisplatin and irinotecan (IP regimen) was reported to be as effective as the EP regimen for SCLC. The aim of this study was to evaluate the response of PDNEC to the combination of IP regimen in one institution.
PATIENTS AND METHODS

PATIENTS
We retrospectively evaluated the clinical courses of PDNEC patients diagnosed and treated between September 2005 and April 2011 in the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo.
All patients were diagnosed pathologically. Pathological diagnosis of PDNEC was based on the 2004 World Health Organization criteria for lung cancer (7), including criteria for SCLC and LCNEC. In order to assist the pathological diagnosis, immunohistochemistry was performed using the antibodies for neuroendocrine markers including synaptophysin, chromogranin A and NCAM/CD56. At least one of the neuroendocrine markers had to be positive in diagnosing PDNEC. Patients with well-differentiated neuroendocrine tumors (or carcinoids), Merkel cell tumors, or patients diagnosed with a lung primary (SCLC or LCNEC) clinically were excluded in the current analysis. The primary organ was evaluated based on both radiological imaging and immunohistochemistry. Patients with a lung lesion on chest computed tomography (CT) at diagnosis and positive thyroid transcription factor-1 (TTF-1) in the specimens who were diagnosed as lung primary were excluded.
Patients were staged by utilizing a two-stage system based on that of SCLC (8) . Limited disease (LD) was defined as a tumor localized to the organ of origin and the locoregional lymph nodes that could easily be encompassed within one radiation therapy (RT) treatment portal. Extensive disease (ED) was defined as a tumor spreading beyond one radiation portal or with any metastatic lesion. 2 , recombinant human granulocyte colony-stimulating factor was administered until the leukocyte or neutrophil count was restored.
TREATMENT STRATEGIES
The IP regimen was repeated until disease progression, patient refusal or unacceptable toxicity occurred. If Grade 3 -4 non-hematological toxicity or prolonged Grade 4 hematological toxicity occurred, the dose of CDDP and IP was reduced to 80%. After completion, additional locoregional therapy or palliative therapies were performed if appropriate. Prophylactic cranial irradiation was not performed.
EVALUATION
For measurable disease, responses were evaluated using CT and magnetic resonance imaging according to the response evaluation criteria in solid tumors, version 1.1. The National Center Institute Common Terminology Criteria for Adverse Events (version 4.0) was used to evaluate toxicity. Using the Kaplan -Meier method, the progression-free survival (PFS) and overall survival (OS) were calculated from the start of the IP regimen to the disease progression and death, respectively. Prognostic factors for OS were compared using a log-rank test and the Cox proportional hazards model (9,10). All statistical tests were two sided.
RESULTS
PATIENTS
Between September 2005 and April 2011, 50 patients were diagnosed with PDNEC in the study institution and 44 were treated with the IP regimen. Six patients never received IP chemotherapy in their clinical courses. Of those, two patients with LD stage of head and neck origin were treated with concurrent chemoradiotherapy with CDDP, according to the treatment strategy for squamous cell head and neck carcinoma (11) . Two patients were treated with multimodal therapy including surgery, radiotherapy and chemotherapy other than the IP regimen. The remaining two patients died without receiving any therapy because of aggressive progression.
There were 26 males and 18 females. The median age at diagnosis was 60 years (range: 26 -80). The primary sites were as follows: 9 gastrointestinal, 18 head and neck, 4 urinary tract, 1 gynecologic organ and 12 unknown primary origins. Eight patients had lung metastases, 15 patients had bone metastases and 13 patients had liver metastases at diagnosis. Fourteen patients had LD, whereas 30 had ED. Although these 14 LD patients were considered for locoregional therapy before the IP regimen, neither the surgical treatment nor the curative radiation therapy was performed because of local invasion. All these patient characteristics are summarized in Table 1 .
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IMMUNOHISTOCHEMICAL RESULTS FOR PDNEC
Synaptophysin was evaluated in 43 patients and shown to be positive in 39 patients (91%), chromogranin A was positive in 30 patients out of 41 patients evaluated (73%) and CD56/ NCAM was positive in 37 patients out of 42 patients evaluated (88%). TTF-1 was also evaluated in 36 patients and tumors of 8 patients were positive. TTF-1 is usually used for a pathological marker of primary lung cancer, but all of the eight patients with TTF-1 immunoreactivity proved to have no lung lesions closely examined by chest CT at diagnosis. Therefore, they were regarded as extrapulmonary tumors clinically.
TREATMENT Forty-four patients received chemotherapy with the IP regimen. Among these patients, 28 patients were treated with IP as a first-line therapy, whereas 16 patients received one or more therapies (surgery, radiation therapy and/or other chemotherapy regimens) before IP. As for chemotherapy, 35 patients were chemo-naïve and 9 patients had a history of systemic chemotherapy. After the IP regimen, 30 patients received other curative or palliative therapies, including radiotherapy for 15 patients, surgical operation for 5 and salvage chemotherapy for 18. There were 16 patients who received therapies with curative intent after the IP regimen, radiotherapy for 11, surgical operation for 3 and other chemotherapy for 3 patients; 5 patients relapsed after curative therapies. In 14 LD patients, 8 patients received curative therapies and 3 patients relapsed. The other 14 patients received palliative therapies after progression. Salvage chemotherapy regimens consisted of IP monotherapy, amrubicin, S-1, combined carboplatin and paclitaxel, and combined cisplatin and EP. Table 2 ). In patients receiving the IP regimen as first-line therapy, the response rate was 64%, whereas in patients receiving other therapies before IP regimen, the response rate was 25%. The median follow-up time was 11.4 months (range: 1.2 -46.9 months). The median PFS of the IP regimen chemotherapy was 4.8, and median OS was not reached (Fig. 1A and B) . The 1-year, 2-year and 3-year survival rates were 67, 42 and 21%, respectively. Although LD patients tended to have a better PFS and OS, there was no statistical significance for either of them ( Fig. 1C and D) . Median PFS for patients receiving the IP regimen as first-line chemotherapy was 7.3 months, whereas the median PFS was 3.6 months for patients who had already received any other chemotherapy before the IP regimen; there was a significant difference (P ¼ 0.003). However, no statistical significance was shown for the OS by the log-rank test (P ¼ 0.848; Fig. 2A and B) . No significant difference was seen among the primary organs of PDNEC.
TOXICITY
The major adverse events of IP therapy are shown in Table 3 . Grade 3 or 4 hematological adverse events were seen in 29 patients (66%), most of them being leukocytopenia or neutropenia. Grade 3 or 4 non-hematological adverse events were seen in 20 patients (45%). Hyponatremia was the most frequently seen severe nonhematological adverse event (18%). Although 18 patients (41%) needed to reduce the treatment dose and 2 patients had to discontinue the IP due to adverse events, no therapy-related death was seen in this treatment period. One patient discontinued the IP regimen because of a Grade 2 skin eruption that occurred after every infusion of IP. The other patient suffered from febrile neutropenia and septic shock during the first course of the IP regimen.
PROGNOSTIC FACTOR
Finally, we examined the prognostic factors of the IP regimen for these patients. Old age (.60 year old), poor ECOG PS (.1), ED stage, presence of prior chemotherapy, post-chemotherapy, presence of particular lesions (lung, liver and bone) and elevation of serum tumor markers [neuronspecific enolase (NSE) and Pro-GRP] were evaluated in the univariate analysis. Of them, old age and NSE elevation were shown to be prognostic factors for poor OS (P ¼ 0.031 and 0.012, respectively, Fig. 2C and D) . Multivariate analysis also showed a statistically significant relationship with elevation of serum NSE level and poor OS (P ¼ 0.016, hazard ratio, 6.261, 95% CI: 1.400 -27.998). 
DISCUSSION
Until now, no standard chemotherapeutic regimen has been established for PDNEC. In this study, our retrospective analysis demonstrated that the IP regimen was moderately effective and feasible, suggesting that the IP regimen could be considered as a treatment option for PDNEC. Noda et al. (5) reported from the prospective clinical trial for the ED SCLC patients that the IP regimen showed a better response rate and a more improved prognosis than the EP regimen. However, after that, Hanna et al. (6) again compared the IP regimen with EP in a randomized phase 3 study, which showed that the IP regimen and EP regimens had almost the same response, although the doses and schedules used were different from the previous study. Recently, Jin et al. (12) reported their clinical experience with cisplatin and IP for 15 EPSCC patients, although the treatment schedule was different. In our study, the treatment schedule was the same as that of Noda's study. In general, ED-stage patients have a very poor prognosis. Haider et al. (13) reported on the prognoses of 101 EPSCC patients diagnosed in Saskatchewan, Canada, from 1971 to 2002. In their study, the median OS of LD patients was 34 months, much longer than the median OS of ED patients, which was only 2 months. Moreover, ED-stage PDNEC patients with unknown primary origin have very poor prognoses. Though some case reports showed a long survival of LD-stage PDNEC patients with unknown primary origin, median survivals of ED-stage patients with unknown primary have been less than 1 year (14) .
In retrospective studies, a platinum-based regimen and a doxorubicin-based regimen were used for PDNEC patients and they showed moderate responses, but long-term prognoses are poor (12,15 -17) . Hainsworth et al. (17) reported moderate response and OS with a three-drug chemotherapy regimen (paclitaxel, carboplatin and EP), and our study has as same response and survival rate as Hainsworth's study with a two-drug regimen. In our study, two-thirds of our patients were ED stage, and PDNEC patients with unknown primary origin accounted for 24%. The IP regimen is useful for the ED stage, and/or unknown primary PDNEC patients.
In our study, high serum NSE was shown to be a prognostic factor of poor OS in PDNEC patients receiving the IP regimen. Serum NSE is known to be a tumor marker of SCLC, and some investigators have suggested that NSE is related to the prognosis for SCLC. Shibayama et al. (18) evaluated the usefulness of Pro-GRP and NSE for the diagnosis and prognosis of SCLC and in the SCLC patients receiving chemotherapy. CR rate in patients with elevated NSE levels was significantly lower than in patients with normal levels of NSE (18.5% vs. 61.7%, P , 0.001). However, whether NSE is related to the prognosis of PDNEC patients has not yet been evaluated. In earlier studies, Lin et al. (19) reported favorable prognostic factors of PDNEC, based on a retrospective analysis of 90 PDNEC patients; female gender, LD and combined modality treatment are discussed in the article. We found no significant difference in the prognoses of patients based on gender or stage. We need to collect and compare more information about the clinical features and prognoses of PDNEC patients to identify the best prognostic factors.
In conclusion, the IP regimen can be considered as a good treatment option for PDNEC patients, especially patients with unknown primary and ED stage. However, we note that the response rate and PFS were relatively poor in previously treated patients. We should pursue a new salvage treatment option for refractory and relapsed PDNEC in the future.
